• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

CVS Health Could Soon Begin a Bottoming Process

Let's check and see if all their programs and initiatives could help the charts and indicators of CVS.
By BRUCE KAMICH
Mar 17, 2020 | 09:00 AM EDT
Stocks quotes in this article: CVS

In his second "Executive Decision" segment of Mad Money on Monday night, Jim Cramer checked in with Larry Merlo, president and CEO of CVS Health Corp. (CVS) , the drug store chain that has pledged to donate areas of its parking lots for COVID-19 testing.

Merlo explained that they are currently working out the details of how to provide secure areas  for safe, effective testing. He said customers have been stocking up, but so far they've only seen a few spot shortages of merchandise. Merlo said they are working to cover the costs of COVID-19 testing and are also adding zero co-payments for telemedicine to help reduce the need to see a doctor in person. 

In this daily bar chart of CVS, below, we can see that prices peaked back in November. There looks like there has been three waves lower (yes that is very subjective) and prices have retraced all the gains back to last June. I think the risk is out of this name.

Prices are below the declining 50-day moving average line and below the cresting 200-day moving average line. The trading volume has been heavy from late February to now and that suggests that we may have seen some "throw in the towel selling" which can help to identify a low.

The daily On-Balance-Volume (OBV) line has declined from December but the line looks like it has slowed its decline this month.

The Moving Average Convergence Divergence (MACD) oscillator is well below the zero line, but we could see a cover shorts buy signal if prices improve soon. 

In this weekly bar chart of CVS, below, we can see that prices have been retesting the lows of 2019. Prices are below the cresting 40-week moving average line.

The weekly OBV line has been drifting lower the past four months and the MACD oscillator is close to moving below the zero line for an outright sell signal.  

In this daily Point and Figure chart of CVS, below, we have a mixed picture. Yes the software shows a potential downside price target around $40 and that is bearish. The chart also shows that there could be good buying interest in the $52 area as there was good volume by price activity there before. We'll see.  

Bottom line strategy: Technical analysis can be subjective at times. I could easily write something bearish about CVS and no one would blink. I can also find some bullish clues this morning but the weakness in the broad market could easily dominate. For now, let's keep an open mind that CVS has corrected enough and that buyers could be attracted around current levels.

(CVS Health is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CVS? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Healthcare | Pharmaceuticals | Mad Money | Executive Interview | Coronavirus

More from Investing

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login